Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/4/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/4/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/4/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -3.74% | -6.32% | +42.70% | +63.37% | 55.2B | |
| -0.81% | -0.33% | +27.15% | +81.12% | 55.6B | |
| -0.48% | +0.70% | -15.77% | -14.85% | 23.51B | |
| -2.43% | -6.14% | -4.15% | +356.36% | 22.35B | |
| -4.01% | -2.68% | +12.50% | -12.70% | 20.6B | |
| -1.23% | -3.15% | +26.00% | -33.84% | 17.45B | |
| -3.34% | -6.96% | +22.02% | +515.48% | 15.16B | |
| +0.14% | -0.31% | +50.54% | +181.48% | 13.91B | |
| -5.09% | -13.14% | +151.85% | +272.20% | 13.74B | |
| Average | -2.08% | -1.55% | +34.76% | +156.51% | 26.39B | |
| Weighted average by Cap. | -2.24% | -0.46% | +30.47% | +121.48% |
Employees
51
